Published in Nano Lett on May 26, 2007
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev (2008) 3.18
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy. Proc Natl Acad Sci U S A (2009) 2.71
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev (2010) 2.08
Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A (2008) 2.04
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Quantum dots for live cell and in vivo imaging. Int J Mol Sci (2009) 1.67
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Ultrasharp nonlinear photothermal and photoacoustic resonances and holes beyond the spectral limit. Nat Photonics (2011) 1.50
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
Lymphangiogenesis and cancer metastasis. J Cell Mol Med (2009) 1.47
Self-luminescing BRET-FRET near-infrared dots for in vivo lymph-node mapping and tumour imaging. Nat Commun (2012) 1.42
In vivo fiber-based multicolor photoacoustic detection and photothermal purging of metastasis in sentinel lymph nodes targeted by nanoparticles. J Biophotonics (2009) 1.31
In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol (2009) 1.26
Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging. Cancers (Basel) (2010) 1.24
Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem (2009) 1.23
Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) (2009) 1.15
Synthesis and Characterization of Anti-HER2 Antibody Conjugated CdSe/CdZnS Quantum Dots for Fluorescence Imaging of Breast Cancer Cells. Sensors (Basel) (2009) 1.11
Multifunctional Nanoparticles as Biocompatible Targeted Probes for Human Cancer Diagnosis and Therapy. J Mater Chem (2009) 1.11
Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol (Camb) (2013) 1.10
Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat Commun (2014) 1.09
Long-term multimodal imaging of tumor draining sentinel lymph nodes using mesoporous silica-based nanoprobes. Biomaterials (2012) 1.09
Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol (2009) 1.07
Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. Neoplasia (2008) 1.06
In vivo imaging of lymphatic drainage of cerebrospinal fluid in mouse. Fluids Barriers CNS (2013) 1.06
Molecular probes for the in vivo imaging of cancer. Mol Biosyst (2009) 1.01
A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res (2010) 1.01
Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem (2011) 1.00
New approaches to lymphatic imaging. Lymphat Res Biol (2009) 0.99
Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol (2010) 0.98
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Multicolor fluorescence imaging of traumatic brain injury in a cryolesion mouse model. ACS Chem Neurosci (2012) 0.97
Preparation and characterization of highly fluorescent, glutathione-coated near infrared quantum dots for in vivo fluorescence imaging. Int J Mol Sci (2008) 0.96
Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev (2011) 0.94
In vivo cancer targeting and imaging-guided surgery with near infrared-emitting quantum dot bioconjugates. Theranostics (2012) 0.90
Self-illuminating in vivo lymphatic imaging using a bioluminescence resonance energy transfer quantum dot nano-particle. Contrast Media Mol Imaging (2010) 0.90
In a "nutshell": intrinsically radio-labeled quantum dots. Am J Nucl Med Mol Imaging (2012) 0.88
Cadmium-free quantum dots as time-gated bioimaging probes in highly-autofluorescent human breast cancer cells. Chem Commun (Camb) (2012) 0.87
Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system. Biomed Opt Express (2014) 0.87
Latanoprost Stimulates Ocular Lymphatic Drainage: An In Vivo Nanotracer Study. Transl Vis Sci Technol (2013) 0.86
Spatial light modulator based active wide-field illumination for ex vivo and in vivo quantitative NIR FRET imaging. Biomed Opt Express (2014) 0.85
A dual-modal magnetic nanoparticle probe for preoperative and intraoperative mapping of sentinel lymph nodes by magnetic resonance and near infrared fluorescence imaging. J Biomater Appl (2013) 0.85
In vivo molecular imaging using nanomaterials: general in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol (2010) 0.85
Quantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectives. Breast Cancer Res Treat (2015) 0.85
Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine (Lond) (2010) 0.84
Brightness-equalized quantum dots. Nat Commun (2015) 0.83
Lymphatic biodistribution of polylactide nanoparticles. Mol Imaging (2010) 0.83
Imaging the lymphatic system. Microvasc Res (2014) 0.82
Synthesis and characterization of quantum dot-polymer composites. J Mater Chem (2009) 0.81
Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther (2013) 0.81
Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. Expert Opin Med Diagn (2011) 0.80
Evaluation of anti-inflammatory drug-conjugated silicon quantum dots: their cytotoxicity and biological effect. Int J Mol Sci (2013) 0.80
Synthesis of luminescent near-infrared AgInS2 nanocrystals as optical probes for in vivo applications. Theranostics (2013) 0.79
Activatable organic near-infrared fluorescent probes based on a bacteriochlorin platform: synthesis and multicolor in vivo imaging with a single excitation. Bioconjug Chem (2014) 0.79
Near-Infrared Fluorescent Materials for Sensing of Biological Targets. Sensors (Basel) (2008) 0.79
Wide-field in vivo background free imaging by selective magnetic modulation of nanodiamond fluorescence. Biomed Opt Express (2014) 0.78
Quantum dots for molecular diagnostics of tumors. Acta Naturae (2011) 0.78
Preparation of compact biocompatible quantum dots using multicoordinating molecular-scale ligands based on a zwitterionic hydrophilic motif and lipoic acid anchors. Nat Protoc (2015) 0.78
A novel controlled-release system for antibacterial enzyme lysostaphin delivery using hydroxyapatite/chitosan composite bone cement. PLoS One (2014) 0.78
In vivo biodistribution studies and ex vivo lymph node imaging using heavy metal-free quantum dots. Biomaterials (2016) 0.77
Autofluorescence-free in vivo multicolor imaging using upconversion fluoride nanocrystals. Lasers Med Sci (2009) 0.77
Multifunctional MRI/PET Nanobeacons Derived from the in Situ Self-Assembly of Translational Polymers and Clinical Cargo through Coalescent Intermolecular Forces. Nano Lett (2015) 0.76
Multiplexed fluorescence mediated tomography with temporal and spectral data. J Biomed Opt (2016) 0.75
In vivo biodistribution and behavior of CdTe/ZnS quantum dots. Int J Nanomedicine (2017) 0.75
Facile Preparation of Multifunctional WS2 /WOx Nanodots for Chelator-Free (89) Zr-Labeling and In Vivo PET Imaging. Small (2016) 0.75
Nanotechnology and regenerative therapeutics in plastic surgery: The next frontier. J Plast Reconstr Aesthet Surg (2015) 0.75
Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Advances in fluorescent-image guided surgery. Ann Transl Med (2016) 0.75
Current and future lymphatic imaging modalities for tumor staging. Biomed Res Int (2014) 0.75
Tumor Regulation of Lymph Node Lymphatic Sinus Growth and Lymph Flow in Mice and in Humans. Yale J Biol Med (2017) 0.75
Quantum dots in imaging, drug delivery and sensor applications. Int J Nanomedicine (2017) 0.75
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem (2002) 4.54
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (2008) 2.75
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
Highly sensitive fluorescence probes for nitric oxide based on boron dipyrromethene chromophore-rational design of potentially useful bioimaging fluorescence probe. J Am Chem Soc (2004) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol (2013) 1.76
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol (2008) 1.68
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
Improvement and biological applications of fluorescent probes for zinc, ZnAFs. J Am Chem Soc (2002) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Highly sensitive near-infrared fluorescent probes for nitric oxide and their application to isolated organs. J Am Chem Soc (2005) 1.41
Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm (2008) 1.39
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39
Evolution of group 14 rhodamines as platforms for near-infrared fluorescence probes utilizing photoinduced electron transfer. ACS Chem Biol (2011) 1.38
A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Clin Cancer Res (2007) 1.38
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res (2007) 1.37